PROGEN — Prostatype Genomics AB Share News
0.000.00%
Last trade - 00:00- SEK52.52m
- SEK52.13m
- SEK0.59m
Brief: Prostatype Genomics Says Running Costs Are Reduced By About 30% (Approx Sek 9 Million On An Annual Basis) Without Affecting Sales And Continued Research.
Brief: Prostatype Genomics Says CFO Michael Af Winklerfelt Is Leaving The Company
Brief: Prostatype Genomics - Prostatype Superior In New Study Published In The Prostate
Brief: Prostatype Expects Significantly Better Performance In Q3
Brief: Prostatype Genomics Q1 EBITDA Loss At SEK 7.3 Mln
Brief: Prostatype Genomics Performs Directed Share Issue
Brief: Prostatype Genomics: Final Outcome Of Preferential Share Issue
Brief: Prostatype Genomics Announces Preliminary Outcome Of Share Issue
Brief: Prostatype Genomics Appoints Professor Gerald Andriole As CMO
Brief: Prostatype Genomics To Cooperate With Spanish Eurofins Megalab
Brief: Prostatype Genomics Decides On Rights Issue Of About SEK 34.3 Mln
Brief: Prostatype Q4 EBITDA Loss SEK 7.7 Million
Brief: Prostatype Genomics, Life Genomics Enter Agreement
Brief: Prostatype Genomics Q3 Oper Loss Widens To SEK 7.6 Mln
Brief: Prostatype Genomics AB Says Sales In 2022 Are Estimated To Amount To Sek 700,000
Brief: Prostatype Genomics Q2 Operating Loss Widens To SEK 7.4 Million
Brief: Prostatype Announces Outcome Of Rights Issue Of Units
Brief: Prostatype Genomics Q1 EBITDA Loss At 5.1 Mln
Brief: Prostatype Genomics Starts Cooperation With Capio Solna Urologi